Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.
Authors not listed
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 2021
Abstract
Popular topic: A clinical trial comparing the immunogenicity of recombinant New Coronavirus vaccine (CHO cells) among people aged 3 to 17 and 18 to 59 years of age.
Overall design:Non inferiority test design was used to evaluate the immunogenicity of the vaccine inoculated to the age group of 3\~17 and the age of 18\~59. The non inferiority hypothesis test was conducted with the results of immunogenicity of the 18-59 year old group in China in the phase III clinical trial of recombinant New Coronavirus vaccine (CHO cell).
Study population:400 healthy people aged 3 to 17 years old, both male and female.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2021). A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age. <em>Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT05109598
Vancouver
Anonymous. A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. 2021.
BibTeX
@misc{anon2021AClini,
title = {A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.},
author = {Anonymous},
journal = {Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2021
Open access · US-GOV
A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2020
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2021
Open access · US-GOV
Clinical Study on Immunogenicity and Safety of Recombinant Novel Coronavirus(COVID-19)Vaccine (CHO Cell) Combined With Tetravalent Influenza Virus Lysis Vaccine in People Aged 18 Years and Over
Shanghai Institute Of Biological Products 2025
Open access · US-GOV
Randomized, Blinded, Controlled Phase I/Ⅱ Clinical Trial Evaluating the Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) for Healthy Individuals Aged 40 Years and Above
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2021
Open access · US-GOV
Clinical Study on the Immunogenicity and Safety of the Recombinant Novel Coronavirus(COVID-19)Vaccine (CHO Cell) 0-1-6 Month and 0-1-4 Month Immunization Programs in People Aged 18 and Above
Ab&B Bio-tech Co., Ltd.JS 2025
Open access · US-GOV